Pacira BioSciences Inc (PCRX)
25.77
-0.28
(-1.07%)
USD |
NASDAQ |
Apr 30, 11:58
Pacira BioSciences Cash from Financing (Quarterly): -1.779M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.779M |
| September 30, 2023 | -27.79M |
| June 30, 2023 | 0.44M |
| March 31, 2023 | -153.90M |
| December 31, 2022 | -58.51M |
| September 30, 2022 | -7.775M |
| June 30, 2022 | -153.66M |
| March 31, 2022 | -181.58M |
| December 31, 2021 | 361.41M |
| September 30, 2021 | 3.052M |
| June 30, 2021 | 5.908M |
| March 31, 2021 | 10.32M |
| December 31, 2020 | 10.36M |
| September 30, 2020 | 209.76M |
| June 30, 2020 | 3.464M |
| March 31, 2020 | -1.281M |
| December 31, 2019 | -2.02M |
| September 30, 2019 | 1.423M |
| June 30, 2019 | 3.737M |
| March 31, 2019 | 0.53M |
| December 31, 2018 | 3.528M |
| September 30, 2018 | 2.982M |
| June 30, 2018 | 2.025M |
| March 31, 2018 | 0.419M |
| December 31, 2017 | 2.28M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.688M |
| June 30, 2017 | 2.338M |
| March 31, 2017 | 216.86M |
| December 31, 2016 | 1.07M |
| September 30, 2016 | 0.769M |
| June 30, 2016 | 2.381M |
| March 31, 2016 | 3.041M |
| December 31, 2015 | 2.172M |
| September 30, 2015 | 1.823M |
| June 30, 2015 | 2.657M |
| March 31, 2015 | 4.047M |
| December 31, 2014 | 2.736M |
| September 30, 2014 | 2.381M |
| June 30, 2014 | 111.79M |
| March 31, 2014 | 1.964M |
| December 31, 2013 | 0.813M |
| September 30, 2013 | 0.979M |
| June 30, 2013 | 1.187M |
| March 31, 2013 | 86.19M |
| December 31, 2012 | 0.237M |
| September 30, 2012 | 0.25M |
| June 30, 2012 | 64.00M |
| March 31, 2012 | -0.88M |
| December 31, 2011 | 49.13M |
| September 30, 2011 | 0.011M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-181.58M
Minimum
Mar 2022
361.41M
Maximum
Dec 2021
1.136M
Average
0.44M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| Dynavax Technologies Corp | 1.776M |
| Arbutus Biopharma Corp | 3.807M |
| Chimerix Inc | 0.062M |
| Karyopharm Therapeutics Inc | 0.264M |
| FibroGen Inc | -0.246M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 47.58M |
| Cash from Investing (Quarterly) | 8.374M |
| Free Cash Flow | 139.49M |
| Free Cash Flow Per Share (Quarterly) | 0.6647 |
| Free Cash Flow to Equity (Quarterly) | 47.93M |
| Free Cash Flow to Firm (Quarterly) | 45.79M |
| Free Cash Flow Yield | 9.89% |